Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
HDAC inhibitors enhanced apoptosis-inducing potential of TRAIL in breast cancer
September 1st, 2005
Histone deacetylase (HDAC) inhibitors might enhance the apoptosis-inducing potential of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). "HDAC inhibitors induce differentiation and/or apoptosis in a variety of cell types by activating transcription of target genes. Activation of the death receptor (DR) pathway by TRAIL induces apoptosis preferentially in cancer cells," scientists in the United States reported. "Here, we investigated the intracellular mechanisms by which HDAC inhibitors (suberoylanilide hydroxamic acid, m-carboxycinnamic acid bis-hydroxamide, MS-275 and trichostatin A) enhance the apoptosis-inducing potential of TRAIL...
Source: Women's Health Weekly (2005-09-01)
|
